| abstract |
The present invention relates to compounds with the formula (I), or a pharmaceutically acceptable satt thereof, formula (I), wherein: R' is selected from the group consisting of (C1--C6)alkyl, -(CR3R4),(C3-C12)cycloalkyl, -(CR3R4), (C6-C12)aryl, and -(CR3R4)t(410)-membered heterocyclyl; b and k are each independently selected from 1 and 2; j is selected from the group consisting of 0, 1, and 2; t, u, p, q, and v are each independently selected from the group consisting of 0, 1, 2, 3, 4, and 5; T is a (6-10)-membered heterocyclyl containing at least one nitrogen atom; R2 is selected from the group consisting of H, (C1-C6)alkyl, -(CR3R)t(C3-C12)cycloalkyl, -(CR3R4)t(C6-C12)aryt, and -(CR3R4)t(410)-membered heterocyclyl; each R3 and R4 is independently selected from H and (C1-C6)alkyl, the carbon atoms of T, R', R2, R3 and R4 may each be optionally, substituted by I to 5 R5 groups; RRis defined in the claims; The compounds of the present invention are 11 ss-HSD-1 inhibitors, and are therefore believed to be useful in the treatment of diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, depression, hypertension, and metabolic diseases. |